The Italy-headquartered contract research organization (CRO) IRBM has been collaborating with Merck & Co., Inc. (known as MSD outside the US and Canada) since 2010.
IRBM will be applying its capabilities in phage display peptide library design and screening, as well as in chemical peptide synthesis and optimization, according to the company.
“At MSD, evaluating the potential of peptide-based therapeutic candidates is a key part of our discovery strategy,” said Emma Parmee, VP of global discovery chemistry, MSD, in a press release.
“Our R&D peptide group have extensive expertise to help deliver high quality peptide drugs for a wide variety of therapeutic indications,” said Carlo Toniatti, CSO at IRBM. “We are thrilled to be collaborating on this project as part of our mission to advance impactful agents into the clinic.”
